Concert Wealth Management Inc. decreased its position in Intrexon Corp. (NYSE:XON) by 22.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,081 shares of the company’s stock after selling 2,694 shares during the period. Concert Wealth Management Inc.’s holdings in Intrexon Corp. were worth $224,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Aperio Group LLC bought a new stake in shares of Intrexon Corp. during the first quarter worth about $299,000. TIAA CREF Investment Management LLC increased its stake in shares of Intrexon Corp. by 2.3% in the first quarter. TIAA CREF Investment Management LLC now owns 141,930 shares of the company’s stock worth $4,810,000 after buying an additional 3,189 shares in the last quarter. Teachers Advisors Inc. increased its stake in shares of Intrexon Corp. by 8.9% in the first quarter. Teachers Advisors Inc. now owns 37,984 shares of the company’s stock worth $1,287,000 after buying an additional 3,104 shares in the last quarter. BlackRock Inc. increased its stake in shares of Intrexon Corp. by 321.0% in the first quarter. BlackRock Inc. now owns 5,780 shares of the company’s stock worth $195,000 after buying an additional 4,407 shares in the last quarter. Finally, BlackRock Group LTD increased its stake in shares of Intrexon Corp. by 9.1% in the first quarter. BlackRock Group LTD now owns 33,713 shares of the company’s stock worth $1,143,000 after buying an additional 2,816 shares in the last quarter. 84.05% of the stock is currently owned by institutional investors and hedge funds.
Intrexon Corp. (NYSE:XON) traded down 2.24% during midday trading on Friday, hitting $26.68. The company had a trading volume of 1,346,810 shares. The firm’s market capitalization is $3.16 billion. The firm’s 50 day moving average is $27.37 and its 200-day moving average is $27.86. Intrexon Corp. has a 52 week low of $18.52 and a 52 week high of $43.76.
Intrexon Corp. (NYSE:XON) last issued its earnings results on Tuesday, August 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.16. Intrexon Corp. had a negative net margin of 96.65% and a negative return on equity of 19.00%. The business had revenue of $52.50 million for the quarter, compared to the consensus estimate of $53.78 million. During the same period in the previous year, the firm earned ($0.37) EPS. The company’s revenue was up 17.0% compared to the same quarter last year. On average, equities research analysts expect that Intrexon Corp. will post ($1.36) EPS for the current fiscal year.
XON has been the topic of a number of analyst reports. Stifel Nicolaus reissued a “buy” rating and set a $57.00 price target on shares of Intrexon Corp. in a research report on Wednesday, June 29th. Wunderlich reissued a “buy” rating and set a $50.00 price target on shares of Intrexon Corp. in a research report on Thursday, July 7th. JMP Securities reissued a “buy” rating on shares of Intrexon Corp. in a research report on Sunday, July 17th. Zacks Investment Research raised Intrexon Corp. from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a report on Tuesday, July 19th. Finally, Vetr downgraded Intrexon Corp. from a “strong-buy” rating to a “sell” rating and set a $22.26 target price on the stock. in a report on Wednesday, July 20th. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $41.71.
In other Intrexon Corp. news, SVP Nir Nimrodi bought 4,000 shares of the stock in a transaction on Monday, August 29th. The shares were acquired at an average price of $26.12 per share, with a total value of $104,480.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 55.10% of the company’s stock.
Intrexon Corp. Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.
Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp. (NYSE:XON).
Receive News & Ratings for Intrexon Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corp. and related companies with MarketBeat.com's FREE daily email newsletter.